Hoosier Cancer Research Network (HCRN) is proud to share that an article written by former HCRN team members, Tim Breen and Adelai Neal, titled, “The Endpoints Dataset: A Quality Control Method for Review and Analysis of Critical Efficacy Endpoints Data,” has been published in the Spring Issue 2024 of the Journal of the Society for Clinical Data Management (JSCDM).

This design manuscript addresses a quality control method required to meet the needs of risk-based quality management systems with respect to critical data elements.

The objective of the manuscript is to describe a quality control method, the endpoints dataset, to ensure that critical efficacy endpoints data are identified and managed to guarantee fitness for purpose and support good decision making.

Jeff Smith, HCRN’s chief operating officer, said “The work described by our former team members represents the culmination of years of dedicated effort focused on generating high-quality clinical trial data. This work not only enables efficient analysis by our study statistics teams but also supports and guides our risk-based approach to clinical data management. It is the cornerstone of our data export processes, and I am proud to see it published so that other organizations can benefit from the methods developed and refined by our team.”

Read the full article: https://www.jscdm.org/article/id/174/

About Hoosier Cancer Research Network: 

Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.